Evaluate Safety and Efficacy of Innovative Medical Devices for Colostomy Patients

Colostomy Stoma Clinical Trial

Official title:

HydrustomaC3 - Randomized Clinical Trial to Evaluate Safety and Efficacy of Innovative Medical Devices for Colostomy Patients

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05466721
• Other study ID #: HydrustomaC3
• Status: Completed
• Phase: N/A
• Start date: June 13, 2022
• Est. completion date: December 31, 2023

Study information

• Verified date: January 2024
• Source: Hydrumedical
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The surgical ostomy process happens when it is necessary to open an organ (such as the intestine) in order to maintain a communication channel with the external environment. The need for ostomy surgery can happen as a result of illness, genetic factors, or trauma. Despite the extensive improvements in colorectal surgery, in case there is a need for total or partial extraction and exteriorization of the large intestine (colostomy), it is often necessary to perform a stoma that connects the end of the preserved intestine to the skin, in which cases it is necessary to place a a colostomy bag for stool collection. Thus, there is a substantial number of patients who need to live with a permanent abdominal stoma that significantly affects their quality of life, implying significant changes, both physical and social. It will then be necessary for patients to adjust their daily routines in order to deal with stoma care.

The primary objective of this study is to evaluate the Hydrustoma C3 medical devices (plate C3, capsule C3, night bag C3) in terms of its efficacy and safety as colostomy devices. It is also a primary objective of this study to compare the health-related quality of life in patients with colostomy when using a control and Hydrustoma C3 devices.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 45
• Est. completion date: December 31, 2023
• Est. primary completion date: December 19, 2023
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 99 Years

Eligibility

Inclusion Criteria:

• Written informed consent;

• Male and Female patients;

• Adult aged = 18;

• Descending and sigmoid colostomy created more than 3 months previously to the beginning of the study;

• Having formed stool and using a flat ostomy appliance;

• Able to understand the study procedures and fill questionaries;

• Able to apply and remove the ostomy device autonomously.

Exclusion Criteria:

• Repeated experiences of leakage with the usual ostomy device,

• Chronically liquid stools,

• Peristomal skin disorders,

• Known allergic reactions to components of the device,

• Receiving chemotherapy, radiation therapy or steroids in the previous month

Related Conditions & MeSH terms

• Colostomy Stoma

Intervention

Device:
• Hydrustoma C3
The participant will use the device for 14 days.
• Coloplast Alterna
The participant will use the device for 14 days.

Locations

Country	Name	City	State
Portugal	Hospital de Braga	Braga
Portugal	Hospital Da Senhora Da Oliveira - Guimarães	Guimarães	Braga
Portugal	Centro Hospitalar do Tâmega e Sousa	Penafiel
Portugal	Centro Hospitalar de Entre o Douro e Vouga	Santa Maria Da Feira
Portugal	Centro Hospitalar de Vila Nova de Gaia/Espinho	Vila Nova De Gaia
Portugal	Centro Hospitalar de Trás-os-Montes e Alto Douro	Vila Real

Sponsors (1)

Lead Sponsor	Collaborator
Hydrumedical

Country where clinical trial is conducted

Portugal, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Efficacy of the device (journal of capsule/bag changes)	Efficacy will be accessed by asking patients to record on a journal/diary, for each capsule/bag change, what was the reason for the change, and the occurrence and level of leakage.	14 days
Primary	Quality of life of the participant (Stoma Quality of Life questionnaire)	In order to compare stoma related quality of life in patients with colostomy when using a control device and the Hydrustoma C3 devices the Stoma Quality of Life questionnaire will be used. This questionnaire is composed of 20 questions. Example of question "I worry that the bag detaches.". All questions must be answered on a scale of 1 to 4, being 1 always and 4 never.	14 days
Primary	Adverse effects	Safety evaluations will be done by monitoring adverse events.	14 days
Primary	Safety of the device (Discolouration, Erosion, Tissue overgrowth score)	Safety evaluations will be done by monitoring the peristomal skin using the validated Ostomy Skin tool (DET score). The DET Score is calculated by examining the peristomal skin and evaluate the skin based on the descriptions in each of the 3 domains, discolouration (D), erosion (E) and tissue overgrowth (T); and assessing the size of the area affected in each of the 3 domains. The total score is (maximum 15) calculated by adding all of the subscores from each domain together.	14 days
Secondary	Satisfaction of the participant (questionnaire)	The patients will be asked to evaluate the medical device in terms of application, discretion of the device, stoma related noise, feelings of security (confidence) and overall satisfaction of use (including comfort and impact on body image). The questionnaire has 8 questions of multiple choice (example "Regarding the safety during usage of the devices, I feel: (1) very insecure; (2) moderately insecure; (3) Moderadately secure; (4) Very secure") and 1 open answer question.	14 days